- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04038931
Collection of Human Liver Biopsy and Whole Blood Samples From T1DM, TP or PP Patients for Potential Use for Insulin Producing Cells in Future Clinical Studies
Collection of Human Liver Biopsy and Whole Blood Samples From Type 1 Diabetes Mellitus (T1DM), Total or Partial Pancreatectomy Patients for Potential Use as an Autologous Source for Insulin Producing Cells in Future Clinical Studies
In this study, liver samples will be collected, processed and stored in a specialized, clinical grade, cell bank for potential future clinical use. A set of ex-vivo immunogenicity and transdiffrentiation tests will be carried to confirm the ability of this cryopreserved cell batch to be used as clinical grade raw material. Biopsies will be collected during TP or PP with the assumption that some of the patients (especially PP patients will not go through Islets autotransplantation) will develop brittle diabetes, thus Orgenesis therapy can provide them in the long run, a treatment. In terms of T1DM the purpose is to have available clinical grade raw material for cell replacement therapy.
The collected liver samples will be proliferated (up to passage 4) for future use. A portion of the stored cells will be utilized in a small-scale process to test possible immunogenicity performed on the collected blood sample. The assay will provide data whether immunomodulation treatment will be required in the future clinical trials. Also the transdffrentiated cells (AIPs) will be tested according to release criteria relevant for clinical IPC production. Liver biopsy donors will be contacted upon approval of the consecutive study and will have study recruitment priority. The donors can refuse to participate in the future study or may not need the therapy, however, their biopsies will be stored for a potential use if required, after the therapy is approved.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients between the ages of 18 and 70 years old, inclusive.
- For T1DM - Patients with history of established T1DM undergoing an elective abdominal surgery with an easy access to the liver
- Patients undergoing total or partial Pancreatectomy
- Female patients who agree not to breastfeed during the study up to at least seven days after the study is completed.
- For T1DM - Receiving multiple daily insulin injections or insulin pump therapy.
- For T1DM - HbA1c ≤10%.
- Willing to sign the study informed consent document.
- In good general health with no infections, or concomitant medical conditions that would influence the outcome of the trial, at the discretion of the Investigator and the Sponsor.
Exclusion Criteria:
- Received any investigational product within 30 days of admission into this study or plan to participate in any other clinical study during the conduct of this study.
- Received methotrexate or other rheumatoid disease modifying agents within the last 6 months.
- Administration of a live vaccine 30 days prior to screening.
- No evidence of liver Cirrhosis or Nonalcoholic Steatohepatitis (NASH, grade 3 and above) within the last month.
- Patients diagnosed with liver viral infections such as HBV, HCV, HIV
- Patients diagnosed with CMV (defined by IgM positive).
Study Plan
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmation of patients' suitability eligibility to participate in future clinical study
Time Frame: 1 year post biopsy collection
|
Defined by a successful AIPs production from their liver biopsy.
|
1 year post biopsy collection
|
Evaluating autoimmune response to AIPs
Time Frame: 1 year post biopsy collection
|
Defined by Mixed Lymphocyte Reaction (MLR) assay based on the patient's PBMCs isolated from whole blood samples and following in-vivo subcutaneous implantation into the patients' arm
|
1 year post biopsy collection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORG-ISR-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Liver biopsy collection
-
University Hospital, ToulouseCompletedNon-alcoholic Fatty Liver DiseaseFrance
-
AdventHealth Translational Research InstituteBerg, LLCRecruitingNon-Alcoholic Fatty Liver DiseaseUnited States
-
Brooke Army Medical CenterCompleted
-
Nottingham University Hospitals NHS TrustRecruitingLiver Diseases | Liver FibrosisUnited Kingdom
-
Emory UniversitySonic IncytesRecruitingNon-Alcoholic Fatty Liver Disease (NAFLD) | Metabolic Dysfunction Associated Steatotic Liver DiseaseUnited States
-
The Cleveland ClinicCompleted
-
Rutgers, The State University of New JerseyTerminatedLiver Disease | Brain DeathUnited States
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingLiver CirrhosisIndia
-
Brigham and Women's HospitalWithdrawn
-
Asian Institute of Gastroenterology, IndiaCompletedNAFLD | Alcoholic HepatitisIndia